<DOC>
	<DOCNO>NCT02620163</DOCNO>
	<brief_summary>To evaluate efficacy safety YH22162 versus telmisartan / amlodipine treatment patient hypertension inappropriately control telmisartan/amlodipine treatment</brief_summary>
	<brief_title>Efficacy &amp; Safety Study YH22162 v Telmisartan/Amlodipine Patients With Hypertension Inappropriately Controlled Telmisartan/Amlodipine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Signed Informed Consent Men woman ≥ 19 year age Essential hypertensive patient 1 . If already take antihypertensive drug , mean sit systolic blood pressure ( MSSBP ) must 140 mmHg ≤ MSSBP &lt; 200 mmHg 2 . If take antihypertensive drug least 4 week , mean sit systolic blood pressure ( MSSBP ) must 160 mmHg ≤ MSSBP &lt; 200 mmHg Patients know suspected secondary hypertension Other exclusion apply</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>